NASDAQ:ALRN - Aileron Therapeutics Stock Price, News, & Analysis

+0.01 (+1.12 %)
(As of 06/19/2019 03:36 AM ET)
Today's Range
Now: $0.90
50-Day Range
MA: $1.19
52-Week Range
Now: $0.90
Volume45,706 shs
Average Volume230,535 shs
Market Capitalization$13.39 million
P/E RatioN/A
Dividend YieldN/A
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALRN



Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share


Net Income$-31,550,000.00


Market Cap$13.39 million
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.13. View Aileron Therapeutics' Earnings History.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Aileron Therapeutics.

What price target have analysts set for ALRN?

3 Wall Street analysts have issued 12-month price objectives for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Aileron Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

What is the consensus analysts' recommendation for Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

Has Aileron Therapeutics been receiving favorable news coverage?

News headlines about ALRN stock have trended very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aileron Therapeutics earned a news sentiment score of -3.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Aileron Therapeutics.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totalling 458,200 shares, a drop of 44.9% from the April 30th total of 831,300 shares. Based on an average daily volume of 204,800 shares, the short-interest ratio is presently 2.2 days. Currently, 5.5% of the shares of the stock are short sold. View Aileron Therapeutics' Current Options Chain.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
  • Mr. Richard J. Wanstall, VP of Fin. & Operations
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (13.72%) and Brave Asset Management Inc. (0.11%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Bioventures Ltd Novartis, Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.

Which institutional investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Brave Asset Management Inc.. Company insiders that have sold Aileron Therapeutics company stock in the last year include Apple Tree Partners Ii Lp and Bioventures Ltd Novartis. View Insider Buying and Selling for Aileron Therapeutics.

Which institutional investors are buying Aileron Therapeutics stock?

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.90.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $13.39 million. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]

MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel